HRT and Blood Work: What to Test, When to Test, and What the Numbers Mean

Why Blood Work Matters Before You Start HRT

Blood work before HRT is not a formality. A pre-treatment panel identifies contraindications, sets the baseline against which every future draw is compared, and helps choose the right route of administration from day one. Without it, a clinician cannot tell whether a symptom like fatigue is from low estrogen, low thyroid, or anemia.

The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement specifies that a thorough medical history and individualized risk assessment should precede any initiation of hormone therapy. [1] Baseline labs are a core part of that assessment.

A pre-HRT panel typically includes: serum estradiol (E2), FSH, LH, total and free testosterone, SHBG, progesterone (if perimenopausal and still cycling), a complete metabolic panel (CMP), CBC, fasting lipid panel, TSH, and fasting glucose or HbA1c. Women with personal or family history of clotting disorders should also have a thrombophilia screen, including Factor V Leiden mutation and prothrombin G20210A, before starting any estrogen. [2]

Oral estrogen raises triglycerides by roughly 20 to 25 percent in susceptible women, so a fasting triglyceride level above 300 mg/dL is a relative contraindication for oral formulations and a strong argument for transdermal estradiol instead. [3] That single data point from a lipid panel can change the entire treatment plan.

Which Specific Markers Go on the Panel

Every marker on an HRT monitoring panel serves a defined clinical purpose. FSH and LH confirm menopausal status: an FSH above 40 mIU/mL on two draws at least four to six weeks apart, combined with 12 months of amenorrhea, meets the clinical definition of menopause per the Stages of Reproductive Aging Workshop (STRAW+10) criteria. [4] Estradiol below 20 pg/mL supports the diagnosis.

Serum estradiol is the primary efficacy marker. Most women achieve adequate vasomotor symptom relief with estradiol levels between 40 and 100 pg/mL, though some require levels up to 200 pg/mL for bone protection. [5] The 2016 Global Consensus Statement on Menopausal Hormone Therapy notes that the minimum effective dose should always be the clinical target, not a specific serum number in isolation. [6]

SHBG rises significantly with oral estrogen (sometimes doubling) and can bind so much free testosterone that libido and energy suffer even when total testosterone looks normal. A concurrent free testosterone draw clarifies whether SHBG elevation is causing androgen deficiency. [7]

Progesterone testing applies specifically to women who are still perimenopausal and cycling irregularly. A day-21 serum progesterone below 3 ng/mL suggests anovulation, which changes the progestogen component of the regimen. Women on systemic estrogen with an intact uterus require a progestogen to prevent endometrial hyperplasia. The Million Women Study (N=1,084,110) found that combined estrogen-progestogen preparations carried a higher breast-cancer relative risk (RR 2.00) than estrogen-only preparations (RR 1.30), data that informs both drug selection and the minimum-effective-dose principle. [8]

Liver enzymes (AST, ALT) matter mainly for oral estrogen because the gastrointestinal first-pass effect raises hepatic estrogen exposure. Transdermal estradiol, which delivers drug directly to systemic circulation, does not require routine liver enzyme monitoring unless the patient has baseline liver disease. [3]

How Fast Does HRT Change Your Blood Work

Most markers shift within the first four to eight weeks after initiation. Serum estradiol reaches steady state within one to two weeks for transdermal patches and gels. [9] FSH suppression typically follows over the subsequent four to six weeks as hypothalamic-pituitary feedback responds to rising estradiol.

Clinical symptoms often improve before labs fully reflect the change. Vasomotor symptoms can start improving within two to four weeks of adequate dosing, though full symptom stabilization takes about three months in most patients. [10] This lag between lab change and symptom change is why the follow-up draw is scheduled at six to twelve weeks, not at two weeks.

Lipid changes on transdermal estradiol are generally modest and favorable. A randomized trial published in the Journal of Clinical Endocrinology and Metabolism found that transdermal 17-beta-estradiol (0.05 mg/day patch) reduced total cholesterol by approximately 4 percent and LDL by about 7 percent at 12 weeks without meaningfully increasing triglycerides. [11] Oral estradiol produced larger LDL reductions but also raised triglycerides by an average of 24 percent in the same study population.

The HealthRX clinical team uses a three-checkpoint monitoring framework: draw at baseline (week 0), at dose stabilization (week 6 to 12), and annually thereafter. If a dose change occurs at any checkpoint, the six-to-twelve-week cycle restarts. This prevents the common clinical error of adjusting a dose before it has reached steady state and then adjusting again based on a transient reading.

SHBG usually rises within four weeks of oral estrogen use and may double by week eight. Women switching from oral to transdermal estradiol frequently see SHBG fall back toward baseline over eight to twelve weeks, with a parallel improvement in free testosterone levels without any change to their testosterone prescription. [7]

Reading Your Results: Target Ranges on HRT

Reference ranges on a standard lab report reflect a population that includes pre-menopausal women, post-menopausal women, and everyone between them. They are not HRT targets. The ranges below reflect consensus guidance for symptomatic postmenopausal women on systemic therapy.

Estradiol: 40 to 100 pg/mL for vasomotor symptom control; 60 to 200 pg/mL if bone protection is the primary goal. Women with persistent hot flashes despite estradiol above 80 pg/mL should be evaluated for other causes before the dose is increased further. [5]

FSH: No strict target, but values falling from above 40 mIU/mL at baseline to below 30 mIU/mL on treatment generally indicate adequate estrogen delivery. Persistently elevated FSH with adequate estradiol levels suggests poor absorption, particularly with gels applied to skin with thick adipose tissue. [12]

Progesterone: On micronized progesterone (Prometrium 100 to 200 mg nightly), serum progesterone typically rises to 2 to 8 ng/mL four to six hours post-dose. A trough draw (morning, before the next dose) will often read below 1 ng/mL, which is expected and does not indicate inadequate endometrial protection. [13]

Lipids: LDL below 100 mg/dL is the general cardiovascular target for low-risk women. Triglycerides should remain below 150 mg/dL; a level above 300 mg/dL on oral estrogen warrants an immediate route switch to transdermal. [3]

Fasting glucose: HRT does not cause diabetes. The Heart and Estrogen/Progestin Replacement Study (HERS, N=2,763) actually found that women on conjugated equine estrogen plus medroxyprogesterone acetate had a 35 percent lower incidence of new-onset diabetes compared with placebo over 4.1 years (P<0.001). [14] Monitoring glucose annually still makes sense given that menopause itself is associated with worsening insulin sensitivity. [15]

How Long Can You Stay on HRT and What Monitoring Changes Over Time

Duration on HRT is an individualized decision. The NAMS 2022 Position Statement states: "For women who initiate HRT for vasomotor symptoms before age 60 or within 10 years of menopause, the benefits are likely to outweigh the risks for most healthy women." [1] There is no arbitrary five-year cutoff supported by current evidence.

Annual labs remain the standard regardless of how long a woman has been on therapy. After five years of use, a mammogram and possibly a pelvic ultrasound to assess endometrial thickness are typically added to the monitoring schedule. The FDA labeling for all systemic estrogen products recommends periodic reassessment of therapy continuation. [16]

Women continuing HRT past age 65 do not require a different core panel, but cardiovascular risk markers (lipids, fasting glucose, blood pressure) deserve closer attention. The WHI Memory Study showed increased dementia risk with conjugated equine estrogen plus medroxyprogesterone acetate initiated after age 65, data that do not apply to younger initiators but underscore the importance of reviewing the risk-benefit balance at each annual visit. [17]

Bone density testing (DEXA scan) at baseline and every two years provides a functional endpoint that complements blood work in women using HRT specifically for osteoporosis prevention. Blood-based bone turnover markers, such as serum CTX (C-terminal telopeptide) and P1NP (procollagen type 1 N-terminal propeptide), can confirm whether estrogen is suppressing bone resorption within six to eight weeks, long before DEXA shows structural change. [18]

Can You Stop HRT Cold Turkey or Do Labs Guide the Taper

Stopping HRT abruptly is not dangerous in the way that stopping certain cardiac medications abruptly can be, but it frequently causes a rapid return of vasomotor symptoms. Gradual dose reduction over two to four months is generally better tolerated. [19]

Blood work does not strictly govern the taper schedule, but a final estradiol draw six to eight weeks after the last dose confirms that levels have returned to the post-menopausal range (below 20 pg/mL). This confirmation matters clinically because some women on low-dose transdermal therapy who taper slowly may have residual estradiol from depot effects in the skin for several weeks. [9]

FSH will rise back above 40 mIU/mL within four to eight weeks of stopping estrogen in most post-menopausal women, confirming withdrawal from exogenous hormones. Women in perimenopause who stop HRT may still have endogenous ovarian activity; their FSH trajectory will be variable and should not be used as the sole indicator of menopausal status. [4]

Lipid panels after stopping are worth repeating at three months for women who had been on oral estrogen, since the triglyceride-raising effect of oral preparations reverses on withdrawal, while LDL-lowering effects also reverse, typically increasing LDL by 5 to 10 mg/dL. [11]

HRT and Pregnancy: What Blood Work Reveals

HRT is not a contraceptive. Perimenopausal women who are still ovulating intermittently can conceive. The FSH level, even when elevated, does not reliably exclude ovulation in perimenopause. A 2018 review in Maturitas confirmed that contraception should be continued for two years after the last natural period in women under 50, and for one year in women over 50, regardless of FSH results. [20]

If a perimenopausal woman on HRT suspects pregnancy, a serum beta-hCG should be drawn immediately. Serum beta-hCG is reliably positive from 10 to 14 days post-conception and will be elevated independently of any HRT formulation currently in use. [21] Exogenous estradiol and progesterone do not produce false-positive beta-hCG results.

A confirmed pregnancy on HRT requires prompt cessation of any progestogen-containing HRT and obstetric referral. Low-dose vaginal progesterone for luteal support in early pregnancy is a separate clinical indication with its own dosing schema and is not the same as systemic HRT. [22]

Women who achieve pregnancy through assisted reproduction and use vaginal progesterone for luteal support through the first trimester should have serum progesterone drawn at 6 to 8 weeks gestation to confirm levels above 20 ng/mL. Below that threshold in a viable pregnancy, the progesterone dose is typically increased. [22]

How to Prepare for Your HRT Blood Draw

Preparation affects accuracy more than most patients realize. Estradiol levels on transdermal preparations vary by where the patch or gel is applied and how recently it was applied. NAMS recommends drawing estradiol at least 24 hours after a patch change or 2 to 4 hours after gel application (for peak) or 12 to 24 hours after (for trough), depending on the clinical question. [1]

For a fasting lipid panel and glucose, 8 to 12 hours of fasting with water only is required. Non-fasting triglycerides can be 20 to 30 percent higher than fasting values and will overestimate cardiovascular risk. [23]

Biotin (vitamin B7) supplementation above 5 mg per day interferes with immunoassay-based hormone tests (including estradiol, FSH, and TSH) by falsely lowering or raising results, depending on the assay format. The FDA issued a safety communication on biotin interference in 2019. [24] Patients should stop biotin supplementation at least 48 to 72 hours before any hormone blood draw.

Draw timing for progesterone matters acutely in cycling perimenopausal women. A day-21 draw (or 7 days after confirmed LH surge) reflects luteal-phase progesterone; a draw at any other time of cycle will underestimate true luteal output. A level below 3 ng/mL on a properly timed draw indicates anovulation. [13]

HRT Monitoring After Dose Changes

Every dose change resets the monitoring clock. A patient moved from a 0.05 mg/day estradiol patch to a 0.1 mg/day patch should have a repeat estradiol and FSH drawn at six to twelve weeks, not at the annual visit. This rule prevents clinical drift, where subtherapeutic or supratherapeutic levels persist for months because follow-up was deferred.

After a route change, such as switching from oral estradiol 1 mg daily to a 0.05 mg/day transdermal patch, direct dose equivalence does not hold. Oral estradiol 1 mg produces mean peak estradiol levels of 30 to 50 pg/mL due to first-pass metabolism, while a 0.05 mg/day patch typically produces steady-state levels of 40 to 60 pg/mL. [9] A blood draw at six weeks after the switch will confirm whether the transdermal dose is delivering an equivalent or higher systemic estradiol level.

Women on compounded bioidentical hormones face particular monitoring challenges because the FDA does not regulate potency consistency in compounded preparations. The Endocrine Society's 2016 Clinical Practice Guideline on Menopausal Hormone Therapy states: "We recommend against the use of compounded hormone therapy except for women who are truly allergic to an FDA-approved product or who require a dose or delivery form not commercially available." [25] For women who do use compounded preparations, more frequent lab draws (every 8 to 10 weeks initially) are appropriate because batch-to-batch variability can shift serum levels substantially.